# Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

Source: https://onco.cc/trials/nct07061951/  
OnCo record `nct07061951` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Mirdametinib in Chronic lymphocytic leukaemia, run by National Cancer Institute (NCI), now recruiting.

## Summary

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia is a phase 2 interventional study registered as NCT07061951 by National Cancer Institute (NCI), with 20 participants planned, started 2026-05-27 and due to reach its primary completion in 2030-02-01. Interventions recorded: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Mirdametinib. Conditions recorded: Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma.

Linked to the drug Mirdametinib because the registry names it among its interventions and Chronic lymphocytic leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07061951
- Phase: 2
- Setting: A Phase 2 Pilot Study of Mirdametinib in Relapsed Refractory Chronic Lymphocytic Leukemia
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT07061951: https://clinicaltrials.gov/study/NCT07061951

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Mirdametinib](https://onco.cc/drugs/mirdametinib/)

---
JSON: https://onco.cc/api/v1/entities/nct07061951.json